US Patent

US12324852 — Administration of benzodiazepine compositions

Method of Use · Assigned to Neurelis Inc · Expires 2032-10-16 · 6y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a method of using benzodiazepine compositions, such as those containing Valium, for nasal administration.

USPTO Abstract

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Drugs covered by this patent

Valium (diazepam) · Generic (originally Roche)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4173`	—	Valium
`U-4173`	—	Valium
`U-4173`	—	Valium

Patent Metadata

Patent number: US12324852
Jurisdiction: US
Classification: Method of Use
Expires: 2032-10-16
Drug substance claim: No
Drug product claim: No
Assignee: Neurelis Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.